EIF2AK2 and neoplasm: Plitidepsin, through its binding to eEF1A2, would release the apoptotic brake imposed by this elongation factor, exposing the frailty of the tumour cells, especially when compared with healthy tissues expressing eEF1A2, and leading them to a PKR-dependent apoptotic cell death.